An ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/CN2015/085721, filed Jul 31, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,291,720 | ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses In force · High confidence UsedRemaining | Akeso Biopharma, Inc. | In force | High confidence | ||
| US 12,447,208 | ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses In force · High confidence | Akeso Biopharma, Inc. | In force | High confidence | ||
| US 10,449,251 | An ANTI-CTLA4 Monoclonal Antibody or Its Antigen Binding Fragments, Pharmaceutical Compositions and Uses In force · High confidence | Akeso Biopharma, Inc. | In force | High confidence | ||
| Application 19/334,022 | Anti-CTLA4 Monoclonal Antibody or its Antigen Binding Fragments, Pharmaceutical Compositions and Uses Pending Not granted | Akeso Biopharma, Inc. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Akeso Biopharma, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.